Bio Green Med Solution, Inc. (BGMSP) EBITDA Margin (2010 - 2026)

Bio Green Med Solution (BGMSP) posted quarterly EBITDA Margin of 31.62% for Q1 2026, down 102.37% quarter-over-quarter from 1335.8% in Q4 2025.

Bio Green Med Solution, Inc. (BGMSP) EBITDA Margin (2010 - 2026) Analysis & Trends

Bio Green Med Solution (BGMSP) has reported EBITDA Margin for 12 consecutive years, with 31.62% the latest figure, recorded in Q1 2026.

In Q1 2026, EBITDA Margin changed N/A year-over-year to 31.62%; the TTM figure through Mar 2026 stood at 467.48% (changed N/A YoY), while the FY2024 annual figure was 27916.28%, down 2185604.0% from the prior year.
EBITDA Margin slipped to 31.62% in Q1 2026 per BGMSP's latest filing, from 1335.8% in the prior quarter.
Across five years, EBITDA Margin topped out at 1335.8% in Q4 2025 and bottomed at 91100.0% in Q2 2024.
Historically, EBITDA Margin has averaged 21052.1% across 4 years, with a median of 15017.24% in 2024.
On a YoY basis, EBITDA Margin climbed as much as 2101125 bps in 2024 and fell as far as 8951046 bps in 2024.
Bio Green Med Solution's EBITDA Margin stood at 17290.32% in 2023, then fell by 26 bps to 21770.0% in 2024, then jumped by 106 bps to 1335.8% in 2025, then tumbled by 102 bps to 31.62% in 2026.
Business Quant data shows BGMSP's EBITDA Margin at 31.62% in Q1 2026, 1335.8% in Q4 2025, and 1224.69% in Q3 2025.

Download Data